Imipramine Crescent Pharma

Imipramine, the active ingredient in Imipramine Crescent Pharma, is a tricyclic antidepressant presented as an oral tablet for oral use. It is indicated for the treatment of depression, nocturnal enuresis, and anxiety disorders in adult patients, and works by modulating neurotransmitter levels in the central nervous system.

The product complies with European Union regulatory requirements and is distributed across multiple international markets. GNH USA supplies Imipramine Crescent Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and rigorous manufacturing practices.

Imipramine is a tricyclic antidepressant that acts on mood‑regulating pathways and is used for several clinical conditions. It is prescribed when other first‑line agents are unsuitable or ineffective.

Depression: alleviates depressive symptoms by improving mood, energy levels, and sleep quality in adult patients. Enuresis: reduces the frequency of nocturnal bedwetting, helping both children and adults achieve better nighttime continence. Anxiety disorders: lessens anxiety, tension, and associated physical symptoms, supporting improved daily functioning.

Imipramine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dry mouth - Constipation - Drowsiness or sedation - Blurred vision

Serious or Rare Side Effects: - Cardiac arrhythmias (including QT prolongation) - Seizures - Agranulocytosis or other blood dyscrasias

When prescribing imipramine, several safety considerations should be observed.

Cardiac assessment: evaluate patient’s cardiac history and monitor ECG before initiating therapy. Blood pressure monitoring: check blood pressure regularly, especially in patients prone to hypotension. Discontinuation: avoid abrupt cessation; taper the dose under medical supervision to reduce withdrawal symptoms. Elderly patients: use lower initial doses and monitor for anticholinergic effects. Drug interactions: avoid concomitant use with monoamine oxidase inhibitors or other serotonergic agents. Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Imipramine interacts with several drug classes; careful assessment is required.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe hypertensive crisis or serotonin syndrome. - Selective serotonin reuptake inhibitors (SSRIs) or serotonin‑norepinephrine reuptake inhibitors (SNRIs): may precipitate serotonin syndrome. - Strong anticholinergic antihistamines: can exacerbate anticholinergic toxicity.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, quinidine): increase imipramine plasma levels, requiring dose adjustment. - CNS depressants (e.g., benzodiazepines, alcohol): may enhance sedation and drowsiness. - Diuretics or antihypertensives: may potentiate orthostatic hypotension.